Panel proposes sweeping changes to India's drug regulatory system
This article was originally published in Scrip
An expert committee appointed by India's health ministry has recommended a range of reforms to India's drug regulatory system, including the creation of a "Central Accreditation Council" to oversee the accreditation of clinical investigators, institutes and their ethics committees, and a time and "assurance" bound system to decide on clinical trial applications in the country.
You may also be interested in...
The termination of the Aurobindo-Sandoz deal isn’t perhaps all bad news for the Indian firm and the flip side may be an improved balance sheet, according to some analysts. But the resolution of compliance issues at manufacturing facilities remains critical.
Aurobindo and Sandoz mutually terminate their planned $1bn deal, leaving many questions on how both sides will re-orient strategies going forward.
Takeda appoints new country head for India and aims to improve patient access to innovative medicines in the largely out-of-pocket market.